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Summary In an attempt to enhance the anti-tumour immune response, the co-stimulatory molecules B7-1 or B7-2 were expressed on the
surface of B16 melanoma cells. B7-expressing tumours grew more slowly in both syngeneic immunocompetent mice and athymic T cell-
immunodeficient nude mice. The delay in growth of B7-expressing tumours was dependent on natural killer (NK) cells, as reductions in
tumour growth rates were minimized in mice depleted of NK cells. Systemic immunity to B16 melanoma was examined by vaccination with
irradiated tumour cells. Inoculation with irradiated B16 B7-1 cells failed to protect against a subsequent challenge with live parental B16 cells.
but conferred partial protection against challenge with live B16 B7-1 cells. In contrast to the local anti-tumour reaction. this protective
response was dependent on T cells. The results presented here reveal some of the mechanisms involved in the in vivo response to a poorty
immunogenic tumour modified to express co-stimulatory molecules.
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Attempts to modulate the immune response against tumour cells as
a potential therapeutic modality hax-e centred mainly on T cells. as
these represent the immune cell population with antigen speci-
ficity and memon- (Tepper and Mule. 1994: Colombo and Fomi.
1996). An effectixe l-tic response against tumour cells requires
actix ation ofprecytotoxic CD8- T cells bN- cvtokines secreted from
CD4- T helper cells which. in tum. has-e been actix ated by profes-
sional antigyen-presenting cells (APCs) that hax-e taken up antigens
denxied from tumour cells (Pardoll. 1993). In addition. profes-
sional APCs mav also actixate CD8+ cvtotoxic T cells directlx
(Huang et al. 1994). Efficient acti-ation of T cells requires
antigen-non-specific signals. as well as the antigyen-specific signal
receix ed by the T-cell receptor/CD3 complex. An important co-
stimulatorv signal is provided bx the CD28 receptor on T cells
(Linslev and Ledbetter. 1993). the ligands for which belong to the
B7 familN. including B7-1 (CD80) (Freeman et al. 1991) and B7-2
)B70/CD86) (Azuma et al. 1993: Freeman et al. 1993). These co-
stimulatorx molecules are expressed by professional APCs. such
as dendritic cells and macrophages. enabling them to present
antigens effectix-ely to T cells. Co-stimulatory signals give rise to
increased expression of a Xaniety of cytokines that hax e autocnrne
and paracrine effects on the proliferation. actixvation and matura-
tion ofT cells (Gimmi et al. 1991).
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In recent *-ears. it has become evident that many human and
experimental tumours possess specific antigens that may be reco2-
nized bv T cells and that may act as targets for an immune rejec-
tion response (Boon et al. 1994). Such specific antigens haxe been
identified in the B16 murine melanoma (Naftzger et al. 1996:
Bloom et al. 1997). However. as most tumour cells do not express
co-stimulatorv molecules. tumour-specific antigens w-ould fail to
be presented to T cells efficiently. Indeed. this may represent one
mechanism bv which tumour cells evade recognition by the
immune system (Vile et al. 1996).
In x-itro. actixation of cytotoxic T cells may be achieved by
stimulation via the TCR and CD28. without requirement for
exo,genous cyvtokines provided by T helper cells (Azuma et al.
1992a: Harding, and Allison. 1993). In attempts to enhance
immune recognition and autment anti-tumour responses. co-
stimulatorx molecules have been expressed on the surface of
tumour cells. The engineered tumourcell Awould then be capable of
presenting the tumour-associated antigens together with the co-
stimulatory signal directly to T cells. thereby bypassing the
requirement for helper T cells and APCs. B7-expressing tumours
in vivo have elicited an effective local anti-tumour response that is
mediated by CD8- cells independent of CD4- cells. in support of
this model. at least in a primarx response against the tumour (Chen
et al. 1992. Tow-nsend and Allison. 1993). Recently. it has been
shown that the in xivo response against some B7-1-expressing
tumours is mediated primarily by natural killer (NK) cells. instead
of (Geldhof et al. 1995: Yeh et al. 1995). or in addition to. T cells
(Cavallo et al. 1995: Wu et al. 1995). Here. wve report for the first
time that the response against a poorly immunogenic tumour
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tumour cell challenge. Although B7-l-expressing B16 cells were
ineffectix-e in eliciting a protective response against parental B16
cells. they afforded partial protection against B7-1-expressing B16
cells. Unlike the local reaction against the tumour. this response
was T cell dependent. These data raise questions conceminc the
role ofexogenously transferred B7 molecules in the generation of
anti-tumour immune responses in Xix o.
MATERIALS AND METHODS
10o4 Cell cufture
B16 is a long-established murine melanoma cell line (Fidler.
1970). The B16.F1 subline was used in this studv. CMT93 is a
murine colorectal tumour cell line (Franks and Hemmings. 1978).
All cell lines were monitored routinelv and found to be free of
Mlcoplasma infection. The cells were cultured in Dulbecco's
modified Eagle's minimal essential medium supplemented x-ith
10% (vol/xol) fetal calf serum and 4 n-M L-glutamine.
Expression plasmids and transfection of tumour cells
wr Subcloningxwas performedusing standard recombinant techniques
(Sambrook et al. 1989). Plasmid pTyr-B7-1 is a tissue-specific
expression xector where murine B7-1 is drixven by the 5' promoter
of the murine tyrosinase gene (Vile and Hart. 1993: Chong et al.
1996). The expression vector BCMGSNeo-mB70 wvas kindly
provided by Professor M Azuma (Tokyo) (Azuma et al. 1993).
Adherent B16 melanoma cells (1 ) Awere transfected with 10jgc
of plasmid DNA by calcium phosphate precipitation using the
Profection method (Promega. Madison. WI. USA) according, to the
manufacturer's instructions. Cells xxere selected in 1.25 jgc ml-'
puromvcin (Sigma. Poole. UK) or in 5o ml-' G418 sulphate
(Gibco. Paisley. UK). After incubating in selection medium for
3 weeks. surviving colonies were expanded and assayed for trans-
04 ogene expression. B7-1 was expressed in CMT93 cells using, a retro-
viral vector. as described prex iously (Chong et al. 1996).
Figure 1 Expression of B7-1 or B7-2 in parental and gene-modified B16
cells. A Parental B16. B B16 B7-1. C B16 B7-2. Cells were incubated with
mCTLA4-Hyl. indicated by the bold lines, followed by FITC-conjugated rabbit
anti-human IgG as described in Materials and methods. The faint lines
represent control samples in which celts were incubated with normal medium
instead of the fusion protein. The x-axis shows fluorescence on a log,O scale
and the y-axis represents relative cell number
expressinc B7-2 is also NK-cell dependent. as well as confirminn
the involvement of NK cells in the response against a B7-1-
expressing tumour.
Generation of a response agrainst metastatic tumour cells
represents a primary aim of immunotherapy. Therefore. besides
attempting, to elicit a local anti-tumour response. it is also of
importance to investigate x-hether the B7-expressing tumour cells
give nse to systemic protective immunity. Recently. B7-1 tumours
have been shown to elicit a sy,stemic immune response by cross-
primina of host professional APCs. in addition to direct anticnen
presentation to T cells by the tumour cells (Huang et al. 1996:
Cav'eux et al. 1997). Indeed. the former mechanism may be more
effective than direct presentation (Huang et al. 1996).
We examined the abilitv of irradiated. B7-expressing B16 cells
to evoke svstemic protective immunity against a subsequent lixe
Flow cytometry
Expression of B7-1 and B7-2 w-as determined by stainiur with the
fusion protein mCTLA4-Hyl (Lane et al. 1993) (kindly provided
by Dr P Lane. Basle) or the specific monoclonal antibodies 16-10-
Al. hamster IgG (anti-B7-l) (Razi-Wolf et al. 1992) (generously
given by Dr H Reiser. Boston) or GLI. rat IgG, (anti-B7-2)
(Pharmingen. Cambridge. UK). An appropriate fluoroisothio-
cyanate-conjugated secondary antibody as used (all obtained
from Dako. Bucks. UK). The samples (5000 cells) were analysed
using a Becton Dickinson FACScan.
In vivo injection of tumour cells
C57BL/6 mice and BALB/c nude (nulnu) mice were obtained from
colonies bred at the Imperial Cancer Research Fund (Herts. UK).
C57 beige mice (C57BlJ60laHsd-bg) were purchased from Harlan
(Oxfordshire. United Kinadom). The NK cell activitx- of the nude
mice was hiaher than that of C57BUJ6 mice (data not shown).
whereas C57 beige mice were NK cell deficient. Mice were age and
sex matched for individual experiments. Institutional guidelines for
care and welfare of animals were adhered to strictly. To establish
subcutaneous (s.c.) tumours. 1 x I0W cells (experiments involving
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Depletion of natural killer cells
In vivo depletion of NK cells was performed by using 25 gl of
rabbit polyclonal anti-asialo GM1 (Wako. Neuss. Germany). made
up to a volume of 0.2 ml with PBS and injected intravenously
(Habu et al. 1981 ). The animals were challenged with tumourcells
1 day later. Each mouse received a second dose ofantibody 1 w-eek
later. Control mice were injected with normal rabbit serum.
In vitro assay for natural killer cell activity
The assav was based on lvsis of '1Cr-labelled tumour cells by
freshly isolated splenocvtes (Brunner et al. 1976). Target cells
(2 x 106) vere incubated with ["'Cr]sodium chromate (3.4 MBq) for
1 h. washed and suspended at a concentration of 1 x 1( ceHls ml-l
Single cell suspensions ofspleen cells were prepared. An aliquot of
0.1 ml of the effector and target cell suspensions w-as mixed at
variouseffector-target ratios. in replicates ofat least four. and incu-
bated for 4 h. An aliquot of0.1 ml of supematant was aspirated to
determine radioactivity. As a positive control in the assays. spleno-
cytes were obtained from mice that had been injected with 100 mg
of poly [l]:poly [C] (polyinosinicpolycvtidylic acid) 24 h previ-
ously. This agent is a potent inducer ofinterferons and rapidly acti-
vates NK cell activity (Djeu et al. 1979).
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Vaccination of mice with irradiated tumour cells
Tumour cells were suspended in PBS and ifradiated (50 Gy). Mice
were injected s.c. with 5 x I0- irradiated cells (0.1 ml) in the flank
region and two further doses were administered at weekly intervals.
The mice received a live cell challenge (5 x I0 B16 or B16 B7-1
cells. 5 x I0 CMT93 B7-1 cells) in the opposite flank 1 week later.
Statistical analyses
Data from the animal experiments were analysed by plotting
Kaplan-Meier curves using the *occurring event as the time at
which a tumour appeared. A tumour was considered to be present
when a palpable mass >0.2 cm was noted. Different groups of
mice were compared using the log-rank test (Altman. 1991).
30 40
Fgure 2 Growth of parental and B7-1-expressing B16 cells in vivo.
Parental B16 and B16 B7-1 cells (5 x 105 cells per mouse) were injected s.c.
into A immunocompetent C57BU6 mice, B athymic nude BALB/c mice and
C C57 beige mice (ten mice per group). This expeniment was perforrmed in
DaraJIel using the three types of mice and all mice received the same
xreparation of B16 of B16 B7-1 cells. The result with C57BU6 mice is
representative of nine independent experiments, that with nude mice
s representative of seven expenments and that with beige mice is
representative of two experiments.-, B16; - - -. B16 B7-1
NiK cell depletion with anti-asialo GM1) or 5 x lIW cells (all other
~xperiments) were suspended in 0.1 ml of phosphate-buffered
saline (PBS) and injected s.c. into the flank region. Animals were
!xamined daily until the tumour became palpable. whereafter the
liameter. in two dimensions. was measured thrice weekly. Animals
were killed when tumour size reached 1.0 x 1.0 cm. The minimal
umorgenic dose for parental B16 cells is 1 x l0 (s.c.).
RESULTS
Transfection of B7-1 or B7-2 or cDNA into B16
melanoma cells
Parental B16 melanoma cells did not express detectable levels ofB7-
1 orB7-2 (Figure 1). Stable expression ofmunrne B7-1 was achieved
by co-transfection ofplasmid pTyr-B7-1 with a plasmid bearing the
puromycin-resistance gene (Figure 1). Murine B7-2/B70 was
expressed using plasmid BCMGSNeo-mB70 (Figure 1). Expression
ofthese molecules was stable in in vitro culture. up to approximately
ten subcultures. The in vitro growth rates of the B7-expressing
sublines were sim-lilar to the parental line (data not shown).
Expression of the co-stimulatory molecule B7-1 or B7-2
retards the growth rate of B16 melanoma cells in
immunocompetent mice
Subcutaneous injection ofB16 B7-1 cells into syngeneic immuno-
competent C57/BL6 mice resulted in the development of tumours
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(data not shown). In the experiment depicted in Figure 2A. 10/10
mice inoculated with parental B16 cells had developed tumours by
day 9. s-hereas only 1/10 of those given B7-1 cells had formed a
tumour. Similarly. it vas found that expression of B7-2 decreased
the growth rate of B16 melanoma cells in vivo (P<0.01. log-rank
test). In the experiment represented in Figure 3A. tumours had
appeared in all ten mice given parental B16 cells bv day 9.
compared w-ith only 4/10 of mice injected with B16 B7-2 cells.
Control B16 cells transfected with the puromycin or neomycin
selection marker. without B7. gres at the same rate as parental
B16 cells in vivo (data not shown).
Expression of B7-1 or B7-2 also retards the growth rate
of B16 melanoma cells in athymic T-cell
immunodeficient nude mice
A delay in emergence of tumours wvas also observed when B16
B7-1 melanoma cells wvere inoculated into athvmic T-cell immun-
odeficient nude mice (P<0.01. log-rank- test) (Figure 2B).
Moreover. a number of these mice completely rejected the B7-
expressing tumour cells. For instance. 2/10 nude mice injected
with B16 B7-1 cells remained tumour free. w-hereas all the mice
riven parental B16 cells developed tumours (Figure 2B). The
P< 0.05 decreased tumorigenicitv of B16 B7-1 cells in nude mice was
observed in seven other independently repeated experiments (data
not shown). where it was also apparent that the retardation of
growth of B16 B7-1 cells in nude mice was more marked than
that seen in immunocompetent mice. Expression of B7-2 also
30 40 decreased the growth rate of B16 tumours in nude mice consis-
tently (P<0.05. logr-rank test) (Fiaure 3B).
The growth rates of B7-2 and parental tumours were
similar in beige mice
No difference was seen in the growth rates of B7-2 and parental
tumours in C57 beige mice (Figure 3C. However. a delav in
appearance of B7-1 tumours %vas seen compared with parental
tumours (P<0.01. log-rank test) (Figure 2C.
0 10 20
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Figure 3 Growth of parental and B7-2-expressing
B16 and B16 B7-2 cells (5 x 10T cells per mouse) wi
immunocompetent C57BL/6 mice, B athymic nude E
beige mice (ten mice per group). This experiment w
using the three types of mice and all mice received t
B16 or B16 B7-2 cells. The results with C57BU/6 mic
representative of three independent experinments arn
representative of two experiments.-. B16: - - -. B14
in most cases. However. there Aas a delav in
B7-1 tumours. compared wvith tumours resul
of parental B16 cells (P<0.001. log-rank tes
was seen consistently in nine independently
Not
significant
The difference in growth rates between B7-expressing
and parental B16 tumours in nude mice was minimized
by treatment with anti-asialo GM1 antibody
Nude mice that were treated with 25 gl of rabbit poIyclonal anti-
asialo GM1 antibody showed decreased NK cell activity compared
with control mice given normal rabbit serum (NRS). as demon-
strated by an NK cell lysis assay performed using splenocytes
B16 cells in vivo. Parental from these mice against "'Cr-labelled NK-sensitix-e YAC cells
ere injected s.c. into A (data not shon).
3ALB/c mice and C C57 When control NRS-treated nude mice were inoculated %vith as performed in parallel
he same preparatn of parental B16 and B16 B7-1 cells. there was a delav in the emer-
ce and nude mice are oence of B7-1 tumours (Figure 4A). in keeping with previous
d that with beige mice is C c '
6 B7-2 results. In contrast. when the same cells were inoculated into anti-
asialo GM1-treated nude mice. there was no delay in the appear-
ance ofthe B7-1 tumours (Fiaure 4B).
Similar results were seen when B7-2 and parental B16 cells
the appearance ofthe w-ere compared. Thegrowth rate ofB16 B7-2 cells was retarded in
Itinr from inoculation control NRS-treated nude mice (Figure 4C) but the difference
t) (Figure 2A). which in the B7-2 and parental lines was markedly diminished w%hen
repeated experiments compared in anti-asialo GM1-treated mice (Figure 4D).
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Figure 5 Generation of systemic protective immunity in immunocompetent
mice by vaccinatin with irradiated parental B16 and B16 B7-1 cells.
C57BL/6 mice were vaccinated with 5 x 1O irradiated parental or B7-1 cells.
as indicated (eight or nine mice pergroup) (three vaccinations atweekly
intervals). One week later, the mice were challenged with 5 x 105 live (A)
parental B16 cells or (B) B16 B7-1 cells. The figure shows the growth of
tumours arising from the live cell challenge. These results are representative
of three independent sets of experiments. In C, C57BL/6 mice that received
the same vaccinaton schedule were challenged with 5 x 1o6 live CMT93
B7-1 celts (seven mice per group). The figure shows the growth of tumours
arising from the live cell challenge
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Figure 4 Growth of parental, B7-1-expressing cells and B7-2-expressing
B16 cells in nude mice rendered NK-deflcient by treatment with anti-asialo
GM1 antbody. BALB/c nude mice were injected i-v. with (A and C) 25 gl of
normal rabbit serum (NRS) (control mice) or (B and D) 25 gl of anti-asialo
GM1 antbody (eight mice per group). On the fdlowing day, the mice were
challenged with 1 x 10 parental B16 cells and (A and B) B16 B7-1 cells or
(C and D) B16 B7-2 cells. A second injection of antibody was given 1 week
after the first dose. This result is representative of two indepenent
experiments.-, B16; - - -, B16 B7-1 (A and B) and B16 B7-2 (C and D)
30
Expression of B7-1 gave rise to systemic protective
immunity against B7-1-expressing tumour cells
The ability of tumour cells to elicit systemic protective immunity
against parental cells was investigated by vaccination with irradi-
ated tumour cells followed by challenge with live B16 cells. In
immunocompetent mice. vaccination with irradiated parental B16
cells did not result in any protection against challenge with live
parental B16 cells (Figure 5A). Therefore. under these conditions.
B16 tumour cells were poorly immunogenic. Vaccination with
irradiated B7-1 cells did not induce any protective immunity
against live parental B16 challenge either (Figure 5A). In contrast.
vaccination with irradiated B7-1 cells. but not parental B16 cells.
consistently elicited partial protection against challenge with live
B16 B7-1 cells (P<0.02. lo-rank test) (Figure 5B). The majonrty
of miice was completely protected against live cell challenge.
These vaccination experiments were also performed in parallel in
T-cell-immunodeficient athymic nude mice. In these. however.
vaccination with B7-1 cells did not protect against challenge with
live B7-1 cells (Figure 6).
hImunocompetent mice Aerealso vaccinated with irradiated B16
B7-1 cells and subsequently challenged with live B7-1-expressing
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FIgure 6 Lack of systemic protective immunity in T-cell immunodeficient
athymic nude mice following vaccination with irradiated parental B16 and B16
B7-1 cells. BALB/c nude mice were vaccinated with 5 x 105 irradiated
parental or B7-1 cells. as indicated (seven or eight mice per group) (three
vaccinations at weekly intervals). One week later, the mice were challenged
with 5 x 105 live (A) parental cells or (B) B7-1 cells. The figure shows the
growth of tumours arising from the live cell challenge
CMT93 cells. an unrelated svngeneic tumour cell line (Chong et al.
1996). Most of these mice (six of sexven) did not develop tumours
following challenge with CMT93 B7-1 cells and remained tumour
free (Figrure SC). In comparison. mice xaccinated with irradiated
parental B 16 cells and unvaccinated mice dexeloped tumours more
readily. although the difference compared wvith the group vaccinated
%A-ith B 16 B7- 1 cells did not reach statistical significance.
DISCUSSION
We have sho%%-n here that B 16 melanoma cells that express B7-1 or
B7-2 grexx more slowly than parental B 16 cells in immunocompe-
tent synceneic animals. This retardation in growth was dependent
on NK cells. as the B7 tumours also grew more slowly in athymic
nude mice. which possess NK cell actixity but which are largely
deficient in T cells. Also. in nude mice depleted of NK cells. the
difference in crowth rates betxx-een the parental and B7 tumours
w-as minimal. SimilarIv. in NK cell-deficient beige mice. at least in
the case of the B7-2 tumours. the growth rates betxxeen parental
and gene-modified B16 cells did not differ. These results show
clearly the involvement of NK cells in the response against B7-
expressing tumours. although they do not exclude the participation
of other effector cell tx'pes. as is suggested by the delayed grow-th
of B7- 1 tumours in beige mice.
Natural killer cells represent a heterogeneous population of
lymphocytes that possess spontaneous cytolytic activitv against
some tumour cells and. unlike T cells. they are unrestricted bx
antigen specificity (Wkhiteside and Herberman. 1995). NK cells
also secrete a Xariety of cy'tokines that contribute to the actixation
of other cells. includinc T cells. It has been presumed that NK cells
play a role in the response against tumours in vivo as they can
eliminate circulating tumour cells (Riccardi et al. 1980: Barlozzani
et al. 1983). Recently. a subpopulation of NK cells was identified
that is able to extraxvasate. miorate into solid tumour tissue and
function as cytolvtic cells therein (Vujanovic et al. 1995). Also. of
late. there has been considerable progress in the definition of
receptors on NK cells that regulate their activity (Lanier. 1997). A
family of receptors recognizes MHC class I molecules and aener-
ates an inhibitors signal to NK cells. In the mouse these belong to
the L-49 family of proteins. whereas in humans this function is
provided by the familv of killer cell inhibitory receptors (KIR)
(Raulet. 1996). Low expression of MHC class I by tumours such
as B16 melanoma leads to poor recognition by T cells. but may
favour NK cell activation as MHC class I interacts with these
inhibitorv molecules.
The stimulatory receptors on NK cells are not as w-ell under-
stood. but a xarietx of different molecules are assumed to be
responsible for this activity. One family ofreceptors with stimula-
tory activitv is NKR-P1. which recognizes oligosaccharide
moieties on tumour cells (Bezouska et al. 1994). CD28. which is
expressed on murine NK cells. also provides a stimulatory signal
on binding with B7. promoting NK cell proliferation and increased
cxtokine secretion (Nandi et al. 1994). Recently'. B7-1 was
reported to bind to an unidentified receptor on murine NK cells
and trigger cvtolvtic activity (Chambers et al. 1996). Moreover.
this signal was able to oxerride the inhibitory signals imparted by
MHC class I molecules. Human NK cell lines derixved from the YT
line also express CD28. and the cytolytic actixitv ofthese cell lines
is enhanced by the interaction of CD28 with B7 (Azuma et al.
1992b: Montel et al. 1995). Moreoxer. fresh human NK cells haxe
been found to lyse B7-1-expressing, tumour cells preferentiallx
(Dessureault and Gallincer. 1996).
Othergroups have descnrbed Xaried effects ofB7-1 expression on
in xixo growth ofB16 melanoma. In some cases. B7-1 did not affect
thegrowth pattern (Chen et al. 1994: Townsend et al. 1994). whereas
inothers it resulted in complete rejection ofB16 tumours. a response
that was mediated by NK cells and CD8- cells (Wu et al. 1995).
These apparently conflicting results probably reflect differinm levels
of B7-1 expression. as it has been reported that only clones
expressing high levels of B7-1 were rejected completely. whereas
low-expressing clones grew more slow-ly but were not rejected (Xu
et al. 1995). The results we present here are compatible with this
possibility. The clone used in our experiments expressed a compa-
rable level of B7-1 to the low-expressing clone in the latter study.
Under in vitro conditions. B7-expressing, tumour cells were no more
susceptible to lysis by fresh splenocy'tes than were the parental cells
(data not shown). This does not correlate with the in xivo results. but
may simply' reflect the less than ideal nature ofthe in Xitro assay.
As well as the effects on local tumour growth. it is also of
importance to determine the effects of B7 co-stimulatory
molecules on systemic immunity'. In some studies. B7-expressing
tumours have generated protectixe immunity against a subsequent
challenre with parental tumour cells (Caxallo et al. 1995:
Gajewski et al. 1996: Dunussi-Joannopoulos et al. 1996) although
in other studies such tumours did not elicit any protective immu-
nitv (Ramarathinam et al. 1994: Katsanis et al. 1995). Previously.
in the moderately immunooenic tumour model (K1735 murine
melanoma) we demonstrated that B7-expressing tumours may
ex-en reduce the degree of systemic immunity relatixe to that
elicited by the parental tumour (Chonc et al. 1996). In contrast.
B16 melanoma is a tumour of lou intrinsic immunogenicity
British Joumal of Cancer (1998) 78(8), 1043-1050
-
E
a
E
a
E
0
0
E
0 CancerResearch Campaign 1998B7induces NKcell-dependent response 1049
(Dranoff et al. 1993: Vfile et al. 1994). The abilitv of B16 B7-1
cells to elicit systemic protective immunity was examined by inoc-
ulation of irradiated tumour cells followed by challenge with live
tumour cells. Irradiated B7-1 cells failed to evoke any protection
acainst rechallenge with parental B16 cells. in keeping with
reports by other groups (Cavallo et al. 1995: Wu et al. 1995) and
consistent with the observation that B7 is generally weak at
elicitinc systemic immunity a2ainst tumours of low intrinsic
immunogenicitv (Chen et al. 1994).
In contrast. irradiated B16 B7-1 cells consistently protected the
majority of mice against challenge with live B16 B7-1 cells.
Unlike the local response against B7-expressing tumours. protec-
tive immunity was dependent on T cells. as no protection was
evident in athvmic nude mice. A similarphenomenon was noted in
a munne mammarv adenocarcinoma model (Zitvogel et al. 1996).
Similarly. tumour-infiltratin, lymphocytes from a B7-expressing
plasmacvtoma w-ere able to lyse the B7-expressing tumour cells.
but the parental tumour cells were lysed inefficientlI
(Ramarathinam et al. 1994). It is possible. therefore. that an
epitope derived from the B7-1 molecule may act as an antigenic
target against which a memorv T-cell response is directed. In
support of this was the tendency for vaccination w-ith irradiated
B16 B7-1 cells to confer a degree of protection against an
unrelated syngeneic tumour. CMT93. engineered to express B7-1.
Although B7-1 is a 'self' molecule. it mav be that in gene-modi-
fied tumour cells. where B7-1 is expressed out of its normal
context. novel epitopes arise. Alternatively. the requirement for the
live challenge tumour cells to express B7-1 may be a reflection of
the low degree of protective immunity afforded by inoculation
with irradiated B7-1 cells. such that an additional trigger is needed
at the time oflive challenge.
In this report. we confirm reports by others that the local
response against B7-1-expressing B16 melanoma is mediated. at
least in part. by NK cells (Wu et al. 1995). We have also shown
that the reaction to the B7-2-expressing tumour is similar. and this
constitutes the first report describing NK cells as the main effector
cells responsible for an in vivo response against a B7-2-expressing
tumour. The involvement of NK cells in the local response may
help to explain the recent reports concerning the role ofhost APCs
in production of systemic immunity. as elicited by B7-expressing
tumour cells (Huang et al. 1996: Cayeux et al. 1997). It is possible
that NK cells cause local tumour cell lysis. thus making tumour
antigens available in abundance for uptake by professional APCs
attracted to the local environment. and these in tum would then
present the antigens to T cells efficiently. This situation may be
comparable with the systemic immune response associated with
tumour cell lysis resulting from activation ofa 'suicide gene' such
as herpes simplex virus thvmidine kinase with gyanciclovir treat-
ment (Vile et al. 1997). Therefore. although our results sugoest that
B7 molecules. by themselves. have limited therapeutic use. it
may be useful to attempt co-expression of B7 with a cytokine.
such as granulocyte-macrophage colony-stimulating factor
(GM-CSF). which promotes maturation of professional APCs.
This might then enhance systemic immunity acainst poorlI
immunogenic tumours. Experiments to explore such approaches
are currently under way.
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